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Introduction: Although the protocol of 48 Gy in four fractions over 
4 days has been most often employed in stereotactic body radiother-
apy (SBRT) for stage I non–small-cell lung cancer in Japan, higher 
doses are necessary to control larger tumors, and interfraction inter-
vals should be longer than 24 hours to take advantage of reoxygen-
ation. We report the final results of our study testing the following 
regimen: for tumors less than 1.5, 1.5–3, and greater than 3 cm in 
diameter, 44, 48, and 52 Gy, respectively, were given in four fractions 
with interfraction intervals of greater than or equal to 3 days.
Methods: Among 180 histologically proven patients entered, 120 
were medically inoperable and 60 were operable. The median patient 
age was 77 years (range, 29–89). SBRT was performed with 6-MV 
photons using four noncoplanar and three coplanar beams. Isocenter 
doses of 44, 48, and 52 Gy were given to four, 124, and 52 patients, 
respectively.
Results: The 5-year overall survival rate was 52.2% for all 180 
patients and 66% for 60 operable patients. The 5-year local control 
rate was 86% for tumors less than or equal to 3 cm (44/48 Gy) and 
73% for tumors greater than 3 cm (52 Gy; p = 0.076). Grade greater 
than or equal to 2 radiation pneumonitis developed in 13% (10% for 
the 44/48-Gy group and 21% for the 52-Gy group; p = 0.056). Other 
grade 2 toxicities were all less than 4%.
Conclusions: Our first prospective SBRT study yielded reason-
able local control and overall survival rates and acceptable toxicity. 
Refinement of the protocol including dose escalation may lead to 
better outcome.
Key Words: Lung cancer, Stereotactic body radiotherapy, Stage I, 
Dose, Fractionation, Reoxygenation.
(J Thorac Oncol. 2015;10: 960–964)
Stereotactic body radiotherapy (SBRT) is now the first choice of treatment for medically inoperable patients with 
stage I non–small-cell lung cancer (NSCLC) and operable 
patients who refuse surgery.1–3 Recently reported results sug-
gest that SBRT and surgery yield nearly equivalent outcome.4–7 
Owing to the relatively short history, however, the vast major-
ity of previously published data of SBRT, including those in 
very recent publications, are middle-term 3-year data.3,7–10 To 
compare the two modalities, however, longer-term results, at 
least 5-year data, are necessary.
In our previous publication, we reported 3-year results 
of a prospective SBRT study involving three institutions for 
histologically confirmed stage I NSCLC.11 Total doses were 
44–52 Gy in four fractions; larger tumors were treated with 
higher doses, and interfraction intervals of at least 72 hours 
were adopted to efficiently utilize the reoxygenation phenom-
enon. The rationale for this protocol was discussed in detail 
previously.11 Nearly 6 years have passed since the last patient 
was treated with this protocol, so we analyzed the long-term 
results.
PATIENTS AND METHODS
Eligibility Criteria and Patients
Approval was obtained from the institutional review 
boards and informed consent was obtained from all patients. 
Eligibility criteria were: (1) histologically confirmed stage I 
NSCLC diagnosed by chest and upper abdomen computed 
tomography (CT), brain MRI, and bone scintigraphy or fluoro-
deoxyglucose positron emission tomography (FDG-PET); (2) 
greatest tumor diameter less than or equal to 5 cm; (3) World 
Health Organization performance status less than or equal to 
two or performance status three when its cause was not a pul-
monary disease; (4) no prior therapy and no concurrent malig-
nancy; and (5) arterial oxygen pressure greater than or equal 
to 60 mmHg and forced expiratory volume in 1 second greater 
than or equal to 700 ml.
Between May 2004 and November 2008, 180 eligible 
patients entered the study. All completed the planned treat-
ment. Patients were deemed medically inoperable when they 
had a poor pulmonary function (the ratio of forced expiratory 
volume in 1 second to forced vital capacity less than 60% and/
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or the percent vital capacity less than 75%) or other debilitat-
ing conditions that preclude surgery. The patient and tumor 
characteristics are shown in Table 1. Ages ranged from 29 
to 89 years, with a median of 77 years. The longest tumor 
diameter ranged from 12 to 50 mm, with a median of 27 mm. 
The tumor location was classified into central or peripheral 
according to the Radiation Therapy Oncology Group criteria.
Treatment and Evaluation
Our treatment methods were previously described.11,12 
The visible gross tumor volume on CT during three phases 
(under normal breathing, and with breath holding during the 
expiratory and inspiratory phases) was superimposed to rep-
resent the internal target volume (ITV). The planning target 
volume (PTV) margin for the ITV was 5 mm in the lateral 
and anteroposterior directions and 10 mm in the craniocaudal 
direction.
SBRT was delivered with four fractions using static 
three coplanar and four noncoplanar 6-MV photon beams. In 
principle, respective fractions were delivered at intervals of 
greater than or equal to 72 hours, but owing to national holi-
days, patient schedule convenience, and machine availability, 
the actual overall treatment period was 9–21 days (median, 12 
days); in 92% of the patients, it was 10–14 days. The total dose 
at the isocenter was 44 Gy for tumors with a maximum diam-
eter less than 1.5 cm, 48 Gy for tumors of 1.5–3 cm, and 52 
Gy for those greater than 3 cm. The dose calculation algorithm 
was pencil beam convolution with Batho power law correction. 
It was recommended to cover 95% of the PTV with at least 
90% of the isocenter dose, and, in all cases, 95% of the PTV 
received at least 80% of the prescribed dose. Consequently, 
95% of the ITV was covered with greater than or equal to 94% 
of the prescribed dose in all but one case. Dose constraints for 
normal tissues were: (1) volume of the lung receiving 20 Gy, 
less than or equal to 20%; (2) 40 Gy for less than 1 cc of the 
pulmonary artery and esophagus; (3) 36 Gy for less than 10 cc 
of the stomach; and (4) maximum cord dose less than 18 Gy. 
Central and peripheral lesions were treated in the same way.
Chest and upper abdominal CT was performed at 
2-month interval until 6 months, and every 2–4 months there-
after. FDG-PET was performed whenever necessary. Local 
recurrence was diagnosed by serial CT examinations com-
bined with FDG-PET and/or biopsy (two patients). Pleuritis 
carcinomatosa unaccompanied by local recurrence was 
regarded as distant metastasis. Toxicity was evaluated using 
the Common Terminology Criteria for Adverse Events version 
3. Follow-up after 5 years was conducted at the discretion of 
the attending radiation oncologist.
Statistical Analysis
For survival and failure-free rate analyses, the Kaplan–
Meier method (from SBRT start) and log-rank test were 
employed. To evaluate isolated lymph node (regional) failure, 
patients were censored when they developed local recurrence 
or pulmonary metastasis. To evaluate isolated distant metasta-
sis, patients were censored when they developed local and/or 
regional recurrence. The local status was followed until death 
and patients were not censored even when they developed 
regional or distant metastasis. Multivariate analysis of potential 
prognostic factors was carried out using the Cox proportional 
hazards model. In doing multivariate analysis, patients were 
divided into two groups and all the parameters were entered 
as dichotomous variables. Incidences of adverse events were 
compared using Fisher’s exact and χ2 tests. Statistical softwares 
used were StatView version 5.0 (SAS Institute, Cary, NC) and 
HALWIN (Gendaisuugakusha, Kyoto, Japan).
RESULTS
Efficacy
The median follow-up period was 52.5 months for all 
patients and 72.5 months for living patients. Only one patient 
TABLE 1.  Patient and Tumor Characteristics
Characteristic All
Stage IA Stage IB
44 Gy 48 Gy 52 Gy
Maximum tumor diameter (cm) 1.2–5.0 <1.5 1.5–3 >3
Patient number 180 4 124 52
Age (years)
  Range (median) 29–89 (77) 67–81 (74) 55–87 (77) 29–89 (78)
Sex
  Men/women 123/57 2/2 79/45 42/10
Performance status
  0/1/2/3 87/69/21/3 3/0/1/0 63/47/13/1 21/22/7/2
Operability
  Operable/inoperable 60/120 2/2 43/81 15/37
Histology
  Adeno/squamous/NSCLC 104/60/16 4/0/0 74/37/13 26/23/3
Tumor location
  Center/periphery 35/145 0/4 23/101 12/40
Adeno, adenocarcinoma; squamous, squamous cell carcinoma; NSCLC, unclassified non–small-cell lung cancer.
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was lost to follow-up within 3 years. Fifty-five died of the dis-
ease, whereas 39 died of intercurrent disease or committed 
suicide. Overall and cause-specific survival curves and local, 
regional, and distant metastasis control curves for all patients 
are shown in Figure 1. For all patients, overall survival rate was 
52.2%, cause-specific survival rate was 68.0% and local control 
rate was 82.6% at 5 years. The regional and distant metastasis 
control rates at 5 years were 83.8% and 76.3%, respectively.
Figure 2 shows overall survival and local control curves 
according to the tumor size and prescribed dose. No patients 
treated with 44 Gy developed local recurrence. The 5-year 
local control rate was 86% for 124 patients receiving 48 Gy 
and 73% for those receiving 52 Gy. Figure 3 shows overall 
survival and local control curves according to operability. The 
5-year overall survival was 66% for 60 operable patients and 
45% for 120 inoperable patients. The rate was 73% for 45 
operable patients with a T1 tumor and 47% for 15 operable 
patients with a T2 tumor. Survival and control data according 
to potential prognostic factors are summarized in Table 2.
Toxicities
Grade greater than or equal to 2 radiation pneumonitis 
was observed in 24 of the 180 patients (13.3%); grade 3 was 
seen in only two patients (1.1%). Grade greater than or equal to 
2 pneumonitis was seen in 13 of 128 patients (10.2%) with a T1 
tumor and 11 of 52 patients (21%) with a T2 tumor (p = 0.056 
by Fisher exact test and 0.049 by χ2 test). Grade greater than or 
equal to 2 pneumonitis was seen in 8 of 35 patients (23%) with 
a central lesion and 16 of 145 patients (11.0%) with a periph-
eral lesion (p = 0.11 by Fisher exact test and 0.096 by χ2 test). 
Five of the former eight patients and six of the latter 16 patients 
had received 52 Gy. Grade 2 or higher esophagitis, rib fracture, 
and dermatitis were observed in three (1.7%), four (2.2%), and 
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FIGURE 1. Left panel OS (open circle) and CSS (filled 
circle) curves for all 180 patients. Right panel LC 
(open circle), RC (filled circle), and DMC (open trian-
gle) curves for all 180 patients. OS, overall survival; 
CSS, cause-specific survival; LC, local control; RC, 
regional control; DMC, distant metastasis control.
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< 1.5 cm 4       3        3        2       0 0 4        3        3       2        0       0
1.5-3 cm 124   106     78      34      6      2 124     99      70     31       5       1
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FIGURE 2.  Overall survival (left panel) and local 
control (right panel) curves according to the tumor 
size and prescribed dose. Open circle Less than 
1.5 cm in longest diameter, 44 Gy; filled circle 1.5–
3 cm, 48 Gy, open triangle greater than 3 cm, 52 Gy. 
48 Gy versus 52 Gy: p = 0.043 for overall survival 
and 0.092 for local control.
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seven of the 180 patients (3.9%), respectively; all patients with 
grade greater than or equal to 2 rib fracture or dermatitis had a 
peripheral lesion, whereas two of the three patients with grade 
2 esophagitis had a central lesion. Grade 3 pleural effusion and 
grade 2 cardiac effusion were seen in one patient with a periph-
eral lesion and one with a central lesion, respectively (0.6%).
DISCUSSION
For medically inoperable patients, the 5-year survival 
rate of 45% is a marked improvement over conventional 
radiotherapy, and further discussion on the role of SBRT in 
this patient population may be unnecessary. On the other hand, 
SBRT and surgery need to be more deliberately compared in 
operable NSCLC patients. Randomized trials were attempted, 
but sufficient patient accrual was not achieved.7 Because of 
the marked difference in treatment, randomized comparison 
may not be easy, so evaluation of long-term results is the only 
way to discuss this issue at present. Our mature data indicated 
5-year survival of 66%, cause-specific survival of 74%, and 
local control of 88%. These rates may be nearly comparable 
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Operable    60     53     41     23       4       0 60      50     40      22       4        0    
Inoperable 120 93    65     23     3      2 120     86     56      21       2        1    
FIGURE 3.  Overall survival (left panel) and local 
control (right panel) curves for operable (open circle) 
and inoperable (filled circle) patients (p = 0.028 and 
0.31, respectively).
TABLE 2.  Five-Year Data According to Patient and Tumor Characteristics
Characteristic n
Overall Survival
Cause-Specific 
Survival Local Control Regional Control
Distant Metastasis 
Control
%
P (Uni/Multi)
Hazard Ratio %
P (Uni/Multi)
Hazard Ratio %
P (Uni/Multi)
Hazard Ratio %
P (Uni/Multi)
Hazard Ratio %
P (Uni/Multi)
Hazard Ratio
Age (years)
  ≤79 115 59 0.095/0.079 75 0.062/0.055 83 0.85/0.76 84 0.96/0.89 81 0.22/0.27
  ≥80 65 40 0.68 (0.44–1.05) 55 0.58 (0.33–1.01) 81 0.89 (0.40–1.96) 85 0.94 (0.39–2.25) 68 0.68 (0.35–1.35)
Sex
  Men 123 46 0.0086/0.073 63 0.016/0.10 79 0.050/0.24 80 0.031/0.10 74 0.25/0.48
  Women 57 67 1.65 (0.95–2.86) 79 1.85 (0.88–3.87) 90 1.85 (0.66–5.21) 93 2.90 (0.82–10.3) 81 1.34 (0.59–3.03)
T-stage
  T1 128 57 0.035/0.042 73 0.021/0.016 86 0.076/0.15 87 0.063/0.051 79 0.17/0.16
  T2 52 40 0.63 (0.40–0.98) 56 0.49 (0.28–0.87) 73 0.56 (0.25–1.22) 75 0.43 (0.19–1.01) 69 0.60 (0.30–1.22)
Operability
  Operable 60 66 0.028/0.18 74 0.31/0.60 88 0.31/0.70 87 0.40/0.51 79 0.50/0.64
  Inoperable 120 45 0.71 (0.43–1.17) 64 0.85 (0.45–1.59) 79 0.84 (0.35–2.03) 82 0.72 (0.26–1.96) 75 0.84 (0.39–1.78)
Histology
  Adeno 104 57 0.025/0.20 72 0.049/0.27 85 0.078/0.31 86 0.51/0.89 76 0.54/0.74
  Squamous 60 43 0.74 (0.46–1.18) 60 0.71 (0.39–1.31) 75 0.65 (0.28–1.50) 83 1.07 (0.43–2.62) 76 0.88 (0.42–1.86)
Location
  Center 35 53 0.98/0.62 66 0.91/0.66 79 0.49/0.78 76 0.45/0.63 78 0.50/0.41
  Periphery 145 52 0.87 (0.51–1.48) 68 0.85 (0.43–1.72) 84 1.14 (0.46–2.80) 86 1.27 (0.48–3.37) 75 0.68 (0.27–1.69)
Figures in parentheses indicate 95% confidence intervals.
Uni, univariate; Multi, multivariate; Adeno, adenocarcinoma; Squamous, squamous cell carcinoma.
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to or slightly lower than those reported previously for surgery 
in clinical stage I NSCLC. Median age of the 60 operable 
patients was 77 years; the high age might have contributed to 
the slightly lower survival rate. The study reported here is our 
first one, and after this study, we escalated the total dose, con-
sidering the acceptable toxicities in the 44- and 48-Gy groups. 
We now use 48 Gy for tumors with a maximum diameter less 
than 1.5 cm, 50 Gy for tumors of 1.5–3 cm, and 52 Gy in com-
bination with oral S-1 for those greater than 3 cm. The results 
of the newer study will be published in future; a preliminary 
analysis suggests slightly improved results (Miyakawa et al., 
unpublished data, August 2014). Therefore, we would con-
clude that SBRT is a quite efficient alternative to surgery for 
patients who do not wish to undergo surgery.
The local control rate of 86% at 5 years for T1 
tumors is not too poor, but that for T2 tumors (73%) may 
be improved in future. One way is to use different fraction-
ation schedules. We are proposing six to eight fraction SBRT 
for T2 tumors. By employing larger numbers of fractions, 
normal tissue damage can be suppressed, whereas effects 
against tumor are expected to increase owing to better utili-
zation of the reoxygenation phenomenon. In previous stud-
ies using three different murine tumors, reoxygenation was 
not complete within 24 hours after 13–15 Gy irradiation, and 
reoxygenation seemed to proceed further until 72 hours after 
irradiation.13 Therefore, we use the twice-weekly schedule 
for SBRT. Further dose escalation may be feasible and useful 
especially for T2 tumors by employing a greater number of 
beams, IMRT, or particle therapy.14,15
In conclusion, we reported long-term results of our first 
prospective SBRT study. The obtained results appear reason-
able, but the results may be improved by employing higher 
doses, larger fraction numbers, and/or particle therapy. Such 
treatment would be a reasonable alternative to surgery for 
patients who do not wish to undergo surgery.
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